Big biotech embraces direct-to-consumer advertising

Article Abstract:

The Washington, DC-based industry group Pharmaceutical Research and Manufacturers Association (PhRMA) has announced a set of guiding principles for ethical practices in direct-to-consumer advertising (DTC) due to the increased oversight on drug company advertising by the US Food and Drug Administration (FDA). DTC has already seduced a handful of biotech companies, among those that could afford it and could become an integral part of their new product marketing strategy, which would no longer be limited to healthcare professionals.

Product standards, safety, & recalls, Advertising, Public affairs, Advertising Activity, Ethics, Standards, Ethical aspects, Pharmaceutical Research and Manufacturers of America

---

Teva to acquire Chinese biogenerics manufacturer

Article Abstract:

Generics company Teva Pharmaceuticals of Petach Tikva announced informal plans to acquire a manufacturing facility in China to produce biogeneric versions of brand protein product since the Chinese market has increasing chances of profits. Even though most experts believe that entering the biogenerics market through China is a high-risk proposition, Teva's decision is supported and is believed to bring a positive change.

China, Israel, Acquisitions & mergers, Mergers, acquisitions and divestments, Company acquisition/merger, Teva Pharmaceutical Industries Ltd.

---

Biotech jostles with pharma for slice of HIV market

Article Abstract:

A new class of biological HIV/AIDS drugs such as TNX-355 developed by Tanox and PRO-140 developed by Progenics are making their entry into the pharmaceutical market and vying for a share of the HIV market. Both TNX-355 and PRO-140 are entry inhibitor drugs which interfere with an earlier stage of infection, preventing the virus from entering immune cells.

Product development, Drugs, Biological products industry, Antiviral agents, Anti-HIV agents, Tanox Inc., Progenics Pharmaceuticals Inc.

Similar abstracts:

• Abstracts: Earlier stage biotechs attract partners. Changing patent strategies: what will they mean for the industry? Effecting a comprehensive intellectual property strategy using the Madrid protocol
• Abstracts: The impact of cause branding on consumer reactions to products: does products / cause efitE really matter?. The 'Value of Marketing' and 'The Marketing Of Value" in contemporary times- A literature review and research agenda
• Abstracts: Six questions for Denis Weil. Fighting fire with fire: on the flaming of Michael Moore. Caged grief: the Freedom Tower is ground zero's best memorial
• Abstracts: Reexamining the research exemption. Negotiating the RNAi patent thicket. US courts struggle with new patent infringement standards
• Abstracts: Public biotechnology 2004- the numbers. Public biotechnology 2005- the numbers. Public biotechnology 2003 -- the numbers

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.